Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Larson

Showing results (201-210 of 208) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 208 results.
Leukemia|November 24, 2012
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intoleranceE Jabbour, P D le Coutre, J Cortes, et al.
Leukemia|April 11, 2008
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibA Hochhaus, M Baccarani, M Deininger, et al.
Leukemia|June 4, 2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyF J Giles, E Abruzzese, G Rosti, et al.
Leukemia|March 3, 2012
The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemiaS P Whitman, M A Caligiuri, K Maharry, et al.
Leukemia|September 11, 2014
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemiaC Niederwieser, J Kohlschmidt, S Volinia, et al.
Leukemia|March 5, 2020
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemiaA Hochhaus, M Baccarani, R T Silver, et al.
Leukemia|April 12, 2016
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemiaV Madan, P Shyamsunder, L Han, et al.
Leukemia|October 8, 2016
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemiaV Madan, P Shyamsunder, L Han, et al.
Pageof 21

Showing results (201-210 of 208) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 208 results.
Leukemia|November 24, 2012
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intoleranceE Jabbour, P D le Coutre, J Cortes, et al.
Leukemia|April 11, 2008
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibA Hochhaus, M Baccarani, M Deininger, et al.
Leukemia|June 4, 2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyF J Giles, E Abruzzese, G Rosti, et al.
Leukemia|March 3, 2012
The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemiaS P Whitman, M A Caligiuri, K Maharry, et al.
Leukemia|September 11, 2014
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemiaC Niederwieser, J Kohlschmidt, S Volinia, et al.
Leukemia|March 5, 2020
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemiaA Hochhaus, M Baccarani, R T Silver, et al.
Leukemia|April 12, 2016
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemiaV Madan, P Shyamsunder, L Han, et al.
Leukemia|October 8, 2016
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemiaV Madan, P Shyamsunder, L Han, et al.
Pageof 21